Wednesday, June 16, 2021  | 5 ZUL-QAADAH, 1442
Samaa TV
Facebook Twitter Youtube
HOME > News

Chinese coronavirus vaccine shows 50% efficacy in Brazil

No adverse effects have been reported, says Butantan Institute

SAMAA | - Posted: Jan 13, 2021 | Last Updated: 5 months ago
SAMAA |
Posted: Jan 13, 2021 | Last Updated: 5 months ago

Sao Paulo Governor Joao Doria holds Sinovac's CoronaVac vaccine box press conference with information about the Butantan Institute vaccine against Covid-19. Photo: AFP

Listen to the story
The Chinese-developed Coronavac Covid-19 vaccine has demonstrated a 50% efficacy following tests in Brazil, the organization in charge of its production in the South American country said on Tuesday. Coronavac has been given to frontline health care workers in close contact with coronavirus patients. The Butantan Institute repeated its claim from last week that the vaccine is 78% effective in preventing mild cases that needed treatment and showed 100% efficacy in staving off moderate to serious cases. Overall it is 50% effective in preventing patients from contracting the disease, including very mild cases, although not asymptomatic ones. "It's a safe, effective vaccine that ticks all the boxes to justify its use in an emergency," said Butantan director Dimas Covas.  The trial, which was used on 12,500 volunteers, did not produce any adverse effects or significant allergic reactions. "If the vaccine resisted this test, it's going to work infinitely better on a community level," said Ricardo Palacios, the medical manager for clinical trials at Butantan, which is owned by Sao Paulo state and is the largest producer of vaccines in Latin America. Although the vaccine has reached the minimum efficacy target of 50% set by the World Health Organization, it is well behind other vaccines produced by Moderna (94%) and Pfizer/BioNTech (95%). Last Friday, Butantan presented the first vaccine authorization request to Brazil's health regulatory body ANVISA. It was followed just a few hours later by a request from the AstraZeneca/Oxford vaccine makers. Coronavac has been at the center of a political dispute between President Jair Bolsonaro, who has repeatedly tried to discredit it, and its backer Sao Paulo state governor Joao Doria, who is expected to challenge the incumbent at next year's presidential election. Brazil has recorded more than 203,000 deaths from Covid-19 and over eight million cases among its 212 million population. Since November it has witnessed a second wave of infections. Sao Paulo state is due to begin immunizing its 12 million citizens from January 25. Beijing has already sent 10.7 million Coronavac doses and the supplies needed to make another 40 million doses. The health ministry, though, has yet to divulge when it will launch a nationwide immunization program.
FaceBook WhatsApp

The Chinese-developed Coronavac Covid-19 vaccine has demonstrated a 50% efficacy following tests in Brazil, the organization in charge of its production in the South American country said on Tuesday.

Coronavac has been given to frontline health care workers in close contact with coronavirus patients.

The Butantan Institute repeated its claim from last week that the vaccine is 78% effective in preventing mild cases that needed treatment and showed 100% efficacy in staving off moderate to serious cases.

Overall it is 50% effective in preventing patients from contracting the disease, including very mild cases, although not asymptomatic ones.

“It’s a safe, effective vaccine that ticks all the boxes to justify its use in an emergency,” said Butantan director Dimas Covas. 

The trial, which was used on 12,500 volunteers, did not produce any adverse effects or significant allergic reactions.

“If the vaccine resisted this test, it’s going to work infinitely better on a community level,” said Ricardo Palacios, the medical manager for clinical trials at Butantan, which is owned by Sao Paulo state and is the largest producer of vaccines in Latin America.

Although the vaccine has reached the minimum efficacy target of 50% set by the World Health Organization, it is well behind other vaccines produced by Moderna (94%) and Pfizer/BioNTech (95%).

Last Friday, Butantan presented the first vaccine authorization request to Brazil’s health regulatory body ANVISA.

It was followed just a few hours later by a request from the AstraZeneca/Oxford vaccine makers.

Coronavac has been at the center of a political dispute between President Jair Bolsonaro, who has repeatedly tried to discredit it, and its backer Sao Paulo state governor Joao Doria, who is expected to challenge the incumbent at next year’s presidential election.

Brazil has recorded more than 203,000 deaths from Covid-19 and over eight million cases among its 212 million population.

Since November it has witnessed a second wave of infections.

Sao Paulo state is due to begin immunizing its 12 million citizens from January 25. Beijing has already sent 10.7 million Coronavac doses and the supplies needed to make another 40 million doses.

The health ministry, though, has yet to divulge when it will launch a nationwide immunization program.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
 

MOST READ
MOST READ
Karachi to receive monsoon rains in July: Met Office
UAE likely to extend ban on Pakistani arrivals
Firdous Ashiq Awan slaps MNA Qadir Mandokhel on TV show
Demolish Aladin mall, Pavilion End Club in two days: SC
UAE ‘may’ resume Pakistan flights from July 7
Karachi’s Defence, Clifton won’t flood this monsoon: CBC
Supreme Court orders demolition of Karachi’s Nasla Tower
Today’s outlook: Pakistan govt to table Budget 2021-2022
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp